Haematologica (Mar 2013)

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1

  • Ilaria Ambaglio,
  • Luca Malcovati,
  • Elli Papaemmanuil,
  • Coby M. Laarakkers,
  • Matteo G. Della Porta,
  • Anna Gallì,
  • Matteo C. Da Vià,
  • Elisa Bono,
  • Marta Ubezio,
  • Erica Travaglino,
  • Riccardo Albertini,
  • Peter J. Campbell,
  • Dorine W. Swinkels,
  • Mario Cazzola

DOI
https://doi.org/10.3324/haematol.2012.077446
Journal volume & issue
Vol. 98, no. 3

Abstract

Read online

Somatic mutations of the RNA splicing machinery have been recently identified in myelodysplastic syndromes. In particular, a strong association has been found between SF3B1 mutation and refractory anemia with ring sider-oblasts, a condition characterized by ineffective erythropoiesis and parenchymal iron overload. We studied the relationship between SF3B1 mutation, erythroid activity and hepcidin levels in myelodysplastic syndrome patients. Erythroid activity was evaluated through the proportion of marrow erythroblasts, soluble transferrin receptor and serum growth differentiation factor 15. Significant relationships were found between SF3B1 mutation and marrow erythroblasts (P=0.001), soluble transferrin receptor (P=0.003) and serum growth differentiation factor 15 (P=0.033). Serum hepcidin varied considerably, and multivariable analysis showed that the hepcidin to ferritin ratio, a measure of adequacy of hepcidin levels relative to body iron stores, was inversely related to the SF3B1 mutation (P=0.013). These observations suggest that patients with SF3B1 mutation have inappropriately low hepcidin levels, which may explain their propensity to parenchymal iron loading.